Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]